Similarly, despite lack of studies exploring the potentialities of Upadacitinib and Filgotinib in IIM, selective JAK1 inhibition may show considerable efficacy in the management of IFN-I mediated manifestations, such as cutaneous and muscular involvement in DM patients. Here, JAK1 is linked to dermatomyositis.